![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
PH15 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action. It is being evaluated for the treatment to improve psychomotor or cognitive impairment caused by mental fatigue.
Lead Product(s): PH15
Therapeutic Area: Psychiatry/Psychology Product Name: PH15
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024